Berman Capital Advisors’s Editas Medicine EDIT Stock Holding History

Berman Capital Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$0	Buy	+20	New	+$1.1K	﹤0.01%	2104
2021 Q2	–	Sell	-106	Closed	-$4K	–	1932
2021 Q1	$4K	Buy	+106	New	+$6.04K	﹤0.01%	1323
2020 Q1	–	Sell	-24	Closed	–	–	1517
2019 Q4	$0	Buy	+24	New	+$599	﹤0.01%	1480

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Berman Capital Advisors's EDIT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Editas Medicine (EDIT) in Q3 2021: 20 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2104 among its holdings. This is a return to the name: Berman Capital Advisors previously reported a position in EDIT as recently as Q1 2021.

Berman Capital Advisors first reported a position in EDIT in Q4 2019 and has held it in 3 quarters since. The position peaked at $4K in Q1 2021. 319 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

Berman Capital Advisors held 20 shares of Editas Medicine worth $0 as of Q3 2021.
Editas Medicine was a new Berman Capital Advisors position in Q3 2021.
Editas Medicine made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2104 holding.
Berman Capital Advisors first reported a position in Editas Medicine in Q4 2019 and has held it in 3 quarters since.
Berman Capital Advisors's Editas Medicine position peaked at $4K in Q1 2021.
319 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.